Dogwood Therapeutics Announces Director and Officer Changes

Ticker: DWTX · Form: 8-K · Filed: Jul 2, 2025 · CIK: 1818844

Dogwood Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyDogwood Therapeutics, INC. (DWTX)
Form Type8-K
Filed DateJul 2, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, governance, officer-appointment

Related Tickers: DWTX

TL;DR

Dogwood Therapeutics (DWTX) is shuffling its board and exec team, effective June 27.

AI Summary

Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an 8-K on July 2, 2025, reporting changes effective June 27, 2025. The filing details the departure of directors, election of new directors, appointment of certain officers, and updates to compensatory arrangements for specific officers.

Why It Matters

Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.

Risk Assessment

Risk Level: medium — Changes in leadership and executive compensation can indicate internal shifts that may impact future performance.

Key Players & Entities

FAQ

What specific changes were made to the board of directors?

The filing indicates the departure of certain directors and the election of new directors, though specific names are not detailed in the provided excerpt.

Were there any changes in executive officer positions?

Yes, the filing reports the appointment of certain officers.

What is the effective date of these reported changes?

The changes reported in the 8-K filing are effective as of June 27, 2025.

What is the former name of Dogwood Therapeutics, Inc.?

Dogwood Therapeutics, Inc. was formerly known as Virios Therapeutics, Inc.

What is the primary business of Dogwood Therapeutics, Inc.?

Dogwood Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 2, 2025 regarding Dogwood Therapeutics, Inc. (DWTX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing